Speaker
Summary
The future of nuclear medicine would appear to be the paradigm of personalized medicine — targeted radionuclide therapy to spare healthy tissue, and theranostic medicine, which pairs an imaging isotope with a therapeutic isotope to provide simultaneous, real-time dose delivery and verification, leading to drastic reductions in prescribed patient dose.
Candidate isotopes to meet these needs have been identified based on their chemical and radioactive decay properties. The Bay Area Nuclear Data (BAND) Program is currently leading a series of campaigns to perform targeted, high-priority measurements of thin-target cross sections and thick-target integral yields, as part of a larger campaign to address deficiencies in cross-cutting nuclear data needs. These studies will serve to facilitate the production of pre-clinical quantities of radioactivity for emerging and novel medical radionuclides. This talk will focus on the BAND Program’s recent campaigns to measure production cross sections for emerging medical radionuclides.
| Are you interested/eligible for the Young Session? | No, I am not eligible |
|---|
